Answers are grounded in this paper and cite their sources.
In this mini-review the role of CGRP (Calcitonin Gene-Related Peptide) in pain processing pathways and in migraine are discussed. Physiology and pathophysiology of CGRP in non-headache pain as somatic, visceral, inflammatory and neuropathic pain are evaluated. Results are conflicting and it appears that there are no clinical trials establishing the role of CGRP as a sensory pain modulator in non-headache pain. In contrast, the four new anti-CGRP antibodies developed for the prevention of migraine attacksreduce headache frequency in half of patients by 50%.Safety and tolerability during the 3-months trials appear good but long-term safety is unknown. Expected pricing and the potential market size of $ 5billion to $10 billion are discussed.
No takes yet. Share an insight, caveat, or question.
Michael Ab Naafs (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: